Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer And MPP Sign Deal For Generics Of COVID-19 Candidate Paxlovid

Tiered Pricing To Allow Equitable Access To Oral Antiviral

Executive Summary

An agreement allowing the production and distribution of the US firm’s new protease inhibitor in 95 countries has been welcomed by the Medicines Patent Pool. But some medicines access advocates are not so sure it necessarily represents a good deal for lower-income countries.

You may also be interested in...



Shionogi and Medicines Patent Pool Partner To Bring COVID-19 Anti-Viral To 117 Countries

A license agreement between Shionogi and the Medicines Patent Pool aims to widen access to Shionogi’s oral COVID-19 anti-viral ensitrelvir in low to middle-income countries. The investigational drug reduced Omicron-related symptoms in a recent Phase III trial.

WHO Urges Pfizer To Broaden Generic Paxlovid MPP Deal

As Pfizer’s Paxlovid joins the World Health Organization’s prequalification list, the organization has passed down several recommendations to the US-based Big Pharma, including expanding the scope of countries supplied under an MPP generic licensing agreement.

MPP Announces Generic Paxlovid Licences For LMICs

A group of 35 generics manufacturers have signed agreements with the Medicines Patent Pool to supply Paxlovid generics to 95 low- and middle-income countries.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151414

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel